Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is a financially sound company with a solid product portfolio and a strong presence in the global market. With a focus on innovation and plans for future product releases, the company is well-equipped to capitalize on the significant market size for their products. Their vertically integrated approach and strong partnerships give them a competitive advantage and position them for revenue growth. Additionally, improved operations are expected to result in cost savings for the company.

Bears say

Minimed Group is a leader in algorithm development for diabetes management and has seen positive clinical outcomes with its AID systems and smart multiple daily injection (MDI) systems. However, with a projected turnaround to positive cash flow not expected until FY2027 and potential pricing pressure and penetration concerns, the company's profitability and growth potential may be limited. Additionally, regulatory and reimbursement risks, intense competition, and the influence of Medtronic, its parent company, are all potential obstacles to its success.

MMED has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 10 analysts, MMED has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.